

AMENDMENTS TO THE CLAIMS

1-38. (Canceled)

39. (Currently Amended): A method for treating or ameliorating at least one disorder mediated by the CXCR4 receptor which method comprises administering to a subject in need of such treatment or amelioration an effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 1,1'-[1,4-(phenylenebis(methylene))]bis-1,4,8,11-tetraazacyclotetradecane, wherein said disorder is arthritis, lymphoma, non-small lung cancer, vasculature development disease of the gastrointestinal tract, glioblastoma, a disorder comprising basal leukocyte trafficking, or a disorder comprising extravasation and tissue infiltration of leukocytes in response to inciting antigens.

40. (Previously Presented): The method of claim 39 wherein said disorder is arthritis.

41. (Canceled)

42. (Currently Amended): The method of claim 39 wherein said disorder is lymphoma or non-small lung cancer.

43-44. (Canceled)

45. (Canceled)

46. (Previously Presented): The method of claim 39 wherein said disorder is vasculature development disease of the gastrointestinal tract.

47. (Canceled)

48. (Previously Presented): The method of claim 39 wherein said disorder is glioblastoma.

49. (Previously Presented): The method of claim 39, wherein said disorder comprises basal leukocyte trafficking.

50. (Previously Presented): The method of claim 39, wherein said disorder comprises extravasation and tissue infiltration of leukocytes in response to inciting antigens.